Untreated atrial fibrillation in the United States of America: Understanding the barriers and treatment options

Journal of the Saudi Heart Association

Volumn 27, Issue 1, 2015, Pages 44-49

  Verdino, Ralph J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anticoagulation; Atrial fibrillation

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; ENOXAPARIN; HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; CEREBROVASCULAR ACCIDENT; HEART ATRIUM FIBRILLATION; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES;

EID: 84919449325     PISSN: 10167315     EISSN: 22125043     Source Type: Journal    
DOI: 10.1016/j.jsha.2014.09.003     Document Type: Review

References (11)

1. Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med 1999, 131(9):688-695.
2. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet 1994;343(8899):687-91.
3. Chan P.S., Maddox T.M., Tang F., Spinler S., Spertus J.A. Practice-level variation in warfarin use among outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol 2011, 108(8):1136-1140.
4. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
5. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57(11):e101-e198.
6. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137(2):263-272.
7. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 2012, 14(10):1385-1413.
8. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J., Lip G.Y. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010, 138(5):1093-1100.
9. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
10. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
11. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.